Pharmacokinetic Considerations for Treatment of Bacterial Peritonitis during Continuous Ambulatory Peritoneal Dialysis

Bouehet, J. L.; Aparicio, M; Vinçon, G; Demotes‐Mainard, F.; Quentin, C; Bourdenx, Jean-Philippe; Dupoux, J; Potaux, L

doi:10.1159/000419756

Cited by 7 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pharmacokinetics of intravenous (IV) and IP cefotaxime have been studied in patients undergoing CAPD) 19.20] Following IV dose administration, peritoneal clearance was low with little effect on elimination half-life (tY2~) and total body clearance. Only 5% of the IV dose was recovered in dialysate.…”

Section: 2 Cefotaximementioning

confidence: 99%

Clinical Pharmacokinetics During Continuous Ambulatory Peritoneal Dialysis

Taylor

Abdel‐Rahman

Zimmerman

et al. 1996

Clinical Pharmacokinetics

View full text Add to dashboard Cite

Peritoneal dialysis (PD) has gained recognition worldwide as an alternative to haemodialysis in the management of patients with end-stage renal disease. Because the peritoneal catheter provides direct access to the peritoneum, intraperitoneal drug administration has become widely used for the administration of certain drugs. The instillation and drainage of PD fluids contribute to the total body clearance of drugs given by other routes. For most drugs, peritoneal clearance is low. This paper provides an updated review of recently published pharmacokinetic studies involving the administration of selected drugs to patients receiving PD. Antibiotics continue to be extensively studied and administered in PD patients because of the frequent occurrence of infections. Epoetin (recombinant human erythropoietin) has become widely used and is the subject of ongoing pharmacokinetic investigation. Intraperitoneal insulin has become accepted for the treatment of patients with diabetes receiving PD; the pharmacokinetics of vitamin D analogues in PD patients continue to be explored.

show abstract

Section: 2 Cefotaximementioning

confidence: 99%

Clinical Pharmacokinetics During Continuous Ambulatory Peritoneal Dialysis

Taylor

Abdel‐Rahman

Zimmerman

et al. 1996

Clinical Pharmacokinetics

View full text Add to dashboard Cite

show abstract

Compatibility of fosfomycin with different commercial peritoneal dialysis solutions

Kussmann

Baumann

Hauer

et al. 2017

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

For treatment of peritoneal dialysis-related peritonitis, intraperitoneal administration of antibiotics remains the preferable route. For home-based therapy, patients are commonly supplied with peritoneal dialysis fluids already containing antimicrobial agents. The present study set out to investigate the compatibility of fosfomycin with different peritoneal dialysis fluids, namely, Extraneal®, Nutrineal®, Physioneal® 1.36% and Physioneal® 2.27%, under varying storage conditions. The peritoneal dialysis fluid bags including 4 g fosfomycin were stored over 14 days at refrigeration temperature (6°C) and room temperature (25°C) and over 24 h at body temperature (37°C). Drug concentrations over time were determined by using high-performance liquid chromatography coupled to a mass spectrometer. In addition, drug activity was assessed by a disk diffusion method, diluent stability by visual inspection and drug adsorption by comparison of the measured and calculated concentrations. Blank peritoneal dialysis fluids and deionized water were used as comparator solutions. Fosfomycin was stable in all peritoneal dialysis fluids and at each storage condition investigated over the whole study period. The remaining drug concentrations ranged between 94% and 104% of the respective initial concentrations. No significant drug adsorption was observed for any peritoneal dialysis fluid at any storage condition. No relevant reduction of antimicrobial activity was observed. Fosfomycin is compatible with Extraneal®, Nutrineal® and Physioneal® for up to two weeks at refrigeration or room temperature and may be used for home-based therapy. No dose adjustment is needed due to adsorption or degradation.

show abstract

Pharmacokinetics of cefotaxime in dialysis patients

Andrássy

1995

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

Pharmacokinetic Considerations for Treatment of Bacterial Peritonitis during Continuous Ambulatory Peritoneal Dialysis

Cited by 7 publications

References 0 publications

Clinical Pharmacokinetics During Continuous Ambulatory Peritoneal Dialysis

Clinical Pharmacokinetics During Continuous Ambulatory Peritoneal Dialysis

Compatibility of fosfomycin with different commercial peritoneal dialysis solutions

Pharmacokinetics of cefotaxime in dialysis patients

Contact Info

Product

Resources

About